| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1033234500 |
| P356 | DOI | 10.2165/00003495-199244050-00010 |
| P8608 | Fatcat ID | release_xdswbdwe3rgy5mf2azwngtrooy |
| P698 | PubMed publication ID | 1280570 |
| P2093 | author name string | L. B. Barradell | |
| M. M. Buckley | |||
| P2860 | cites work | Heparin pharmacokinetics and pharmacodynamics | Q28318388 |
| Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis | Q33351903 | ||
| Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin | Q33370626 | ||
| An evaluation of the biological response to Fraxiparine, (a low molecular weight heparin) in the healthy individual | Q33395878 | ||
| Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia | Q33454523 | ||
| Severe thrombopenia from heparin: value of the use of low molecular weight heparin. Apropos of 6 cases | Q33458278 | ||
| A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions | Q33458501 | ||
| Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). | Q33460399 | ||
| Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits | Q34692197 | ||
| Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. | Q34692465 | ||
| Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study | Q34693690 | ||
| Binding of low-molecular-weight heparin to aortic endothelium in rabbits. | Q34711171 | ||
| Low molecular weight heparins and hypoaldosteronism | Q35169402 | ||
| Low molecular weight heparin | Q35224749 | ||
| Molecular and cellular biology of blood coagulation | Q35896519 | ||
| Evaluation of the biological effects of low-molecular-weight heparins | Q36345083 | ||
| Effect of low-molecular-weight heparins on laser-induced thrombus formation in rat mesenteric vessels | Q36345088 | ||
| Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis | Q37180937 | ||
| Prophylaxis of postoperative thromboembolism. | Q37238076 | ||
| Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins | Q37568164 | ||
| Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue | Q38346698 | ||
| Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments | Q39815519 | ||
| Pharmacological studies on the low molecular weight heparin derivative CY 216. | Q41811766 | ||
| Endothelial binding sites for heparin. Specificity and role in heparin neutralization | Q41852417 | ||
| Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay | Q43491927 | ||
| Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin | Q43511385 | ||
| Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk | Q43572896 | ||
| Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study | Q43964425 | ||
| Low-molecular-weight heparin Fraxiparin in chronic hemodialysis. A dose-finding study | Q44136929 | ||
| Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations | Q44335174 | ||
| Comparative human pharmacology of low molecular weight heparins | Q44613066 | ||
| Low-molecular-weight heparin (fraxiparine) to prevent deep vein thrombosis in patients undergoing orthopedic surgery: a clinical report of two regimens | Q45719233 | ||
| Thrombopenia caused by low molecular weight heparin | Q45860740 | ||
| Unlike heparin, low-molecular weight heparin does not suppress aldosterone production | Q47172447 | ||
| A standard for low molecular weight heparin? | Q47175726 | ||
| Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins | Q47187862 | ||
| Low-molecular-weight heparin: is small beautiful? | Q47204187 | ||
| In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine | Q47222697 | ||
| Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications | Q47239348 | ||
| Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis | Q47254509 | ||
| Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction | Q47258775 | ||
| Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction | Q47262469 | ||
| Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study | Q47414787 | ||
| Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY 216 and CY 222). | Q47445162 | ||
| The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. | Q53404490 | ||
| An international standard for low molecular weight heparin. | Q53413913 | ||
| Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis | Q67506545 | ||
| The mode of action of CY216 and CY222 in plasma | Q67851726 | ||
| Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial | Q67858192 | ||
| Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood | Q67864626 | ||
| Heparin-induced thrombocytopenia | Q68051868 | ||
| [Prevention of deep venous thrombosis in orthopedic surgery for total hip prosthesis. Randomized trial for determining optimal dosage] | Q68193159 | ||
| A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study | Q68239689 | ||
| Standard heparin but not LMW heparin induces a concomitant increase of t-PA and PAI-1 without modification of global fibrinolysis: Study after 60 days treatment | Q68267311 | ||
| Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure | Q68269804 | ||
| Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight? | Q68337257 | ||
| [Efficacy and tolerance of low molecular weight heparin in the prevention of deep venous thrombosis during non-emergent total hip arthroplasty. A prospective, multicenter trial] | Q68468970 | ||
| Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit | Q68577284 | ||
| Anticoagulant activity in the plasma after a single administration of nebulized heparin or LMW heparin fraction (Fraxiparine) in patients undergoing abdominal surgery | Q68848414 | ||
| Heparin and bleeding: an association with lipase release | Q69058719 | ||
| Evidence for a saturable mechanism of disappearance of standard heparin in rabbits | Q69251026 | ||
| [Thrombopenia caused by fraxiparin. A case] | Q69351498 | ||
| [Clinical tolerance of CY 216 (Fraxiparin) in the prevention of thromboembolic accidents after neurosurgery] | Q69357976 | ||
| Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group | Q69364610 | ||
| Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development | Q69552160 | ||
| Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator | Q69817896 | ||
| [Absence of transplacental passage of Fraxiparin (low molecular weight heparin) during the 3d trimester of pregnancy] | Q69827759 | ||
| Effects of unfractionated and fractionated heparin on platelet function | Q69833063 | ||
| [Biological monitoring of treatment with low molecular weight heparin] | Q69848697 | ||
| [Tolerability in ophthalmologic surgery of CY 216 in preventing venous thrombosis of the leg] | Q69853284 | ||
| Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group | Q69928717 | ||
| Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction | Q70598772 | ||
| Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin | Q70690109 | ||
| Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments | Q93601358 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thromboembolism | Q891391 |
| P304 | page(s) | 858-888 | |
| P577 | publication date | 1992-11-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders | |
| P478 | volume | 44 |
| Q37919151 | Anticoagulating obese patients in the modern era. |
| Q35824873 | Carbohydrate-based therapeutics. |
| Q33495895 | Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients |
| Q35153901 | Heparin therapy. Regimens and treatment considerations |
| Q33499002 | Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders |
| Q53248701 | Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. |
| Q33487898 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders |
| Q40905445 | Pharmacokinetic optimisation of the treatment of deep vein thrombosis |
| Q40504534 | Pharmacokinetic optimisation of the treatment of embolic disorders |
| Q36307908 | Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery |
| Q47196676 | Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis |
| Q47276707 | Subcutaneous low molecular weight heparin in place of heparin infusion during warfarin dose optimisation in cerebral ischaemia |
| Q33488076 | Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders |
Search more.